Explore groundbreaking updates in psoriasis and psoriatic arthritis research from the 2025 AAD Annual Meeting with dermatologist Dr. Mona Shahriari.
Join host Archie Franklin and renowned dermatologist Dr. Mona Shahriari as they unpack the latest research and clinical insights into managing psoriatic disease. This episode dives into head-to-head therapeutic trials, fast-acting treatments for high-impact areas like scalp and nails, and a preview of emerging oral biologics and GLP-1 weight management therapies. Dr. Shahriari discusses real-world challenges in treating psoriasis and psoriatic arthritis, the rise of precision medicine, and how early intervention could alter disease progression.
Whether you're a patient, clinician, or researcher, this conversation delivers critical updates on psoriasis care, including IL-17, IL-23, and TYK2 inhibitors, and their potential to revolutionize dermatology practice.
Timestamps:
-
(00:00) Intro to Psound Bytes & guest welcome Dr. Mona Shahriari
-
(01:00) What the AAD 2025 conference revealed about psoriatic disease
-
(02:10) Comparing IL-17 and IL-23 inhibitors: Trial results
-
(06:00) Treating scalp, palmoplantar, and nail psoriasis
-
(10:45) Genital psoriasis & the importance of psychosocial care
-
(12:00) What’s new for Generalized Pustular Psoriasis (GPP)
-
14:35) The GUIDE Study: Early treatment & immune memory
-
(18:00) Personalized medicine, oral IL-23s & emerging TYK2s
-
(20:00) GLP-1 therapies for weight & inflammation control
-
(23:00) Psoriasis, cardiovascular risk & comorbidities
-
(24:00) Mental health, depression & the value of systemic treatment
-
(26:00) A hopeful future: matching therapy to the patient
4 Key Takeaways:
-
Head-to-head trials show IL-17s like ixekizumab outperform traditional TNF inhibitors and even some IL-23s in early, fast action.
-
Precision therapy based on site (scalp, nails, genitalia) and comorbidities is now guiding real-world treatment selection.
-
GLP-1 medications are emerging as effective adjuncts for psoriasis patients struggling with weight and inflammation.
-
Early intervention—especially with IL-23 inhibitors—may reduce flares, limit disease progression, and improve mental health outcomes.
Guest Bio:
Dr. Mona Shahriari is an Associate Clinical Professor of Dermatology at Yale University and Co-Founder of Central Connecticut Dermatology. A leading voice in inflammatory skin conditions, she serves as Associate Director of Clinical Trials and Senior Editor for the Journal of Psoriasis and Psoriatic Arthritis, a National Psoriasis Foundation peer reviewed journal for health care providers. Dr. Shahriari is also a National Psoriasis Foundation Medical Boa
Popular Podcasts
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.
24/7 News: The Latest
The latest news in 4 minutes updated every hour, every day.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.